Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) S.A.E. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was EGP 381.55 million compared to EGP 314.72 million a year ago. Net income was EGP 70.69 million compared to EGP 45.31 million a year ago. Basic earnings per share from continuing operations was EGP 0.0476 compared to EGP 0.0298 a year ago.
For the nine months, sales was EGP 1,093.05 million compared to EGP 852.49 million a year ago. Net income was EGP 194.9 million compared to EGP 107.08 million a year ago. Basic earnings per share from continuing operations was EGP 0.1289 compared to EGP 0.0703 a year ago.